May the Drug Transporter P Glycoprotein Affect the Antiviral Activity of Human Immunodeficiency Virus Type 1 Proteinase Inhibitors?

Antimicrobial Agents and Chemotherapy- United States

doi 10.1128/aac.44.2.473-474.2000

Full Text

Abstract

Available in

Categories

Infectious Diseases

Date

February 1, 2000

Authors

Publisher

American Society for Microbiology

Related search

Ubiquitination of the Human Immunodeficiency Virus Type 1 Env Glycoprotein

Journal of Virology

English

Antiviral Activity of Polyoxomol Ybdoeuropate PM-104 Against Human Immunodeficiency Virus Type 1.

Chemical and Pharmaceutical Bulletin

English

Determinants of Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Oligomeric Structure.

Journal of Virology

English

Multigene Antiviral Vectors Inhibit Diverse Human Immunodeficiency Virus Type 1 Clades.

Journal of Virology

English

SOSIP Changes Affect Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Conformation and CD4 Engagement

Journal of Virology

English

Human Immunodeficiency Virus Type 1 Vif Inhibits Packaging and Antiviral Activity of a Degradation-Resistant APOBEC3G Variant

Journal of Virology

English

Topogenic Analysis of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein, Gp160, in Microsomal Membranes

Journal of Cell Biology

English

HIV-1 Integrase Inhibitors Are Substrates for the Multidrug Transporter MDR1-P-glycoprotein

Infectious Diseases

English

Antiviral Drug Resistance Mutations in Human Immunodeficiency Virus Type 1 Reverse Transcriptase Occur in Specific RNA Structural Regions.

Antimicrobial Agents and Chemotherapy

Infectious Diseases

English